Ivacaftor

Drug Profile

Ivacaftor

Alternative Names: Kalydeco; Potentiator VX-770; VRT 813077; VX-770

Latest Information Update: 13 Sep 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Cystic Fibrosis Foundation Therapeutics; Vertex Pharmaceuticals
  • Developer Vertex Pharmaceuticals
  • Class Amides; Aminophenols; Quinolones; Small molecules
  • Mechanism of Action Cystic fibrosis transmembrane conductance regulator stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Cystic fibrosis
  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Cystic fibrosis
  • Phase II Chronic obstructive pulmonary disease

Most Recent Events

  • 16 Aug 2017 Vertex Pharmaceuticals initiates enrolment in a phase III trial for Cystic fibrosis (In neonates, In infants, In children) in USA, Australia and United Kingdom (NCT03277196)
  • 01 Aug 2017 The US FDA approves ivacaftor for use in patients with cystic fibrosis (aged ≥2) with one of five residual function mutations that result in a splicing defect in the CFTR gene
  • 28 Jul 2017 Phase-III clinical trials in Cystic fibrosis (Monotherapy) in Israel (PO) (NCT03068312)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top